Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE -- Ignore unavailable to you. Want to Upgrade?

To: Scott H. Davis who wrote (357)	2/3/1999 12:27:00 AM
From: Steve Lokness	Read Replies (1) \| Respond to of 613

I don't know about others, but I'm a real believer in pharmacogenomics as well as a true believer in AXPH. AXPH believes they can become king of the biotechs and I believe as long as Walker remains at the helm that it could happen. Share price was creamed when AXPH picked up SQNA, but todays news looks to be just one of the positives that SQNA brought to the merger. Looks like a win win for AXPH. They get upfront license fee, lots of "stuff" from PPDI and a majority ownership plus PPDI provides financing! Wow! You have to assume that AXPH is also in first position to take advantage of information as it develops. Talk about your undervalued companies! Are there comments as to how the AXPH pharmacogenomics business might stack up against GLGC and CRGN? Steve

To: Scott H. Davis who wrote (357)	2/3/1999 1:24:00 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 613

NOO!, not more symbols to add to the genomics list?! Too many to keep track of already, although Progenitor is gone now at least...but that is old news. I wrote a little summary on only the price action in a few of the genomics stocks for the traderJ thread--I have not doing much trading of late, but I lurk there some of the time. techstocks.com re Gene Logic It was nice to find three brokerage house reports on glgc in the package which came from the company --these guys have not done too well, they all came out with their buys above $7--then watched glgc go to $3 last fall, and only recently rise back to prices seen last summer. Since the stock has doubled since last fall maybe the profit taking will continue a bit longer--and I see the ranking by analysts has fallen from 1.8 to 2.0 (0,5,0,0,0) --today was a bit weak, and I wonder what the large block near the close was all about. Anyway, as far as GLGC for a bioinformatics pick, I have not yet seen anything to scare me off at all, and I understand pretty much what the company is all about now--my notes from the vcall tape even make sense now! Cancer vaccine subthread: Didn't we indentify BIOMF as something to look at on this thread recently? Posts 183, 192 and 195 have references to Biomira..a shame it ran from 3 1/2 to 5 without me--did anybody else get some? --Mike